Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03602079
Other study ID # KlusPharma
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date July 16, 2018
Est. completion date January 12, 2022

Study information

Verified date August 2023
Source Klus Pharma Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.


Description:

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing (NGS) or HER2 expression, defined as at least 1+ by validated immunohistochemistry (IHC) test. The patient must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. Patients will receive study drug as a single IV infusion at the prescribed dose level in each treatment cycle. Cycles will continue until disease progression or unacceptable toxicity. The study is divided into 2 parts (Phase I and Phase II).


Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date January 12, 2022
Est. primary completion date January 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Phase I Patients must meet the following criteria for inclusion into the study: 1. Patients must be able to provide documented voluntary informed consent. 2. Male or female patient = 18 years. 3. Histologically documented, incurable, locally advanced or metastatic cancer. 4. Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease. HER2 expressing is defined in this protocol as HER2 expression of = 1+ determined by validated IHC. 5. Patients should have no available therapy likely to convey clinical benefit. 6. Granulocyte count = 1,500/µL, platelet count = 100,000/µL, and hemoglobin = 9 g/dL. 7. Serum bilirubin = 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase = 2.5 × upper limit of normal (ULN), with the exception of patients with hepatic metastases (ALT and AST = 5 × ULN) and patients with hepatic and/or bone metastases (alkaline phosphatase = 5 × ULN). 8. Creatinine clearance = 50 mL/min calculated by Cockroft-Gault, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or Modification of Diet in Renal Disease (MDRD) formulas. Note that 24 hour urine collection is not required but is allowed. 9. ECOG Performance Status = 1. 10. Women of childbearing potential and men must agree to use an approved method of birth control (e.g., hormonal, barrier) while receiving study drug, and for at least 7 months after the last dose of study drug. Women are excluded from birth control if they had had tubal ligation or a hysterectomy. 11. Patients must have recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. Exclusion Criteria: Phase I: 1. Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New York Heart Association) III or IV, unstable angina pectoris even if medically controlled, history of myocardial infarction during the last 6 months, serious arrhythmias requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular tachycardia). 2. History of Grade = 3 hypersensitivity reaction to trastuzumab. 3. History of any toxicity to trastuzumab that resulted in trastuzumab being permanently discontinued. 4. Symptomatic brain metastases or any radiation or surgery for brain metastases within 3 months of first infusion of study drug. 5. Require supplemental oxygen for daily activities. 6. Documented Grade = 2 peripheral neuropathy. 7. Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks of first infusion of study drug. 8. Any experimental therapy within 4 weeks of first infusion of study drug. 9. Any major surgical procedure within 4 weeks of first infusion of study drug. 10. Diagnosed active liver disease, including viral or other hepatitis, current or history of alcoholism, or cirrhosis. Patients who have positive hepatitis B virus test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti hepatitis B core protein, and positive antibody to the HBsAg (anti-HBs) are not excluded. 11. Have known prior positive test results for human immunodeficiency virus. 12. Uncontrolled hypertension or diabetes. 13. Pregnancy or lactation. 14. Resting corrected QT interval (QTc) > 470 ms at baseline. 15. Left ventricular ejection fraction (LVEF) < 45% determined by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. 16. Prior cumulative doxorubicin dose of > 360 mg/m2 or equivalent.

Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma, Mucinous
  • Bile Duct Cancer
  • Bile Duct Neoplasms
  • Bladder Cancer
  • Breast Neoplasm Malignant Primary
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Renal Cell
  • Cervical Cancer
  • Cholangiocarcinoma
  • Colo-rectal Cancer
  • Cystadenocarcinoma
  • Head and Neck Cancer
  • Head and Neck Carcinoma
  • HER-2 Gene Amplification
  • HER2 Gene Mutation
  • HER2 Positive Gastric Cancer
  • HER2-positive Breast Cancer
  • Laryngeal Neoplasms
  • Larynx Cancer
  • Lip Cancer Stage I
  • Lip Neoplasms
  • Liver Cancer
  • Lung Cancer
  • Mouth Cancer
  • Mouth Neoplasms
  • Mucinous Adenocarcinoma Gastric
  • Mucinous Breast Cancer Recurrent
  • Mucoepidermoid Carcinoma
  • Neoplasms
  • Palate Cancer
  • Pancreatic Cancer
  • Primary Peritoneal Carcinoma
  • Prostate Cancer
  • Prostatic Neoplasms
  • Rare Diseases
  • Rectal Cancer
  • Rectal Cancer Stage I
  • Rectal Cancer Stage II
  • Rectal Cancer Stage III
  • Rectal Neoplasms
  • Recurrence
  • Recurrent Breast Cancer
  • Recurrent Colon Cancer
  • Recurrent Gastric Cancer
  • Recurrent Ovarian Carcinoma
  • Recurrent Prostate Cancer
  • Recurrent Renal Cell Cancer
  • Salivary Gland Cancer
  • Salivary Gland Carcinoma
  • Salivary Gland Neoplasms
  • Salivary Gland Tumor
  • Skin Cancer
  • Solid Tumor
  • Stomach Neoplasms
  • Tongue Cancer
  • Tongue Neoplasms
  • Tonsil Cancer
  • Urologic Cancer
  • Urologic Neoplasms

Intervention

Drug:
A166
A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Cancer Center Boston Massachusetts
United States Mary Crowley Cancer Research Centers - Medical City Dallas Texas
United States Karmanos Cancer Institute Detroit Michigan
United States Virginia Cancer Specialist Fairfax Virginia
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Clinical Research Alliance, Inc. Lake Success New York
United States Stephenson Cancer Center Oklahoma City Oklahoma
United States Providence Cancer Institute Portland Oregon
United States South Texas Accelerated Research Therapeutics, LLC (START) San Antonio Texas
United States Florida Cancer Specialists & Research Institute Sarasota Florida

Sponsors (1)

Lead Sponsor Collaborator
Klus Pharma Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I: Maximum Tolerated Dose Number of patients with dose limiting toxicities Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Phase I: Number of patients with Dose Limiting Toxicities Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03. Every 3 weeks from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Phase I: Number of participants who developed measurable anti-drug antibodies Minimum of 21 days from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary Phase I Maximum observed serum or plasma concentration (Cmax). 84 Days from date of first dose
Secondary Phase I Clearance (CL). 84 Days from date of first dose
Secondary Phase I Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-8]). 84 Days from date of first dose
Secondary Phase I Terminal phase elimination half life (t½). 84 Days from date of first dose
Secondary Phase I Volume of distribution at terminal phase (Vz). 84 Days from date of first dose
Secondary Phase I Volume of distribution at steady state (Vss). 84 Days from date of first dose
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A